Business Context and Reporting Period
This Form 8-K was filed by Amneal Pharmaceuticals, Inc. on February 20, 2020, reporting events occurring on that date. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
- Compensation Grant: Performance-based restricted stock units (PSUs) with a target value of $2.4 million each.
- Recipients: Chirag Patel and Chintu Patel, Co-Chief Executive Officers.
- Effective Date: February 27, 2020.
- Base Salary: $1.00 annually per executive.
- Annual Incentive: None.
Material Changes
The material change reported is the Board's approval of a new long-term incentive compensation program for the Co-CEOs, effective February 27, 2020, under the 2018 Incentive Award Plan.
Guidance, Outlook, and Risks
Performance Conditions: The PSUs are subject to stock price hurdles over a three-year performance period (March 1, 2020, through February 28, 2023).
- 0% to 200% Payout: Earned units range from 0% to 200% of the target based on stock price achievement.
- 50% Threshold: Achieved at a stock price of $8.00 per share.
- 200% Threshold: Achieved at a stock price of $20.00 per share.
- Vesting: Any earned awards vest in full at the end of the performance period.
The filing does not contain general business outlook, risk factors, or contingencies beyond the specific terms of this compensation grant.
Investor Verification Checklist
- Verify the current stock price relative to the $8.00 and $20.00 performance hurdles.
- Confirm the total number of shares underlying the $2.4 million target value based on the grant date price.
- Review the 2018 Incentive Award Plan for additional terms regarding forfeiture or acceleration.
- Monitor future filings for actual vesting outcomes in 2023.